Gamida Cell - GMDA Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GMDA shares.
View GMDA analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12 month target prices for Gamida Cell's shares. Their GMDA share price forecasts range from $6.00 to $22.00. On average, they predict the company's share price to reach $13.83 in the next year. This suggests a possible upside of 308.1% from the stock's current price.
View analysts price targets for GMDA or view top-rated stocks among Wall Street analysts.

Gamida Cell's stock was trading at $2.54 on January 1st, 2022. Since then, GMDA stock has increased by 33.5% and is now trading at $3.39.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our GMDA earnings forecast.

Gamida Cell will be holding an earnings conference call on Monday, August 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Gamida Cell Ltd. (NASDAQ:GMDA) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.15. During the same quarter in the previous year, the firm posted ($0.30) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Enerplus (ERF) and Novan (NOVN).

(GMDA) raised $50 million in an initial public offering on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Gamida Cell's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (1.21%), JPMorgan Chase & Co. (0.89%), Walleye Capital LLC (0.30%) and OLD National Bancorp IN (0.05%).

Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GMDA stock can currently be purchased for approximately $3.39.

Gamida Cell (NASDAQ:GMDA) has a market capitalization of $200.69 million. The company earns $-89,790,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

The company employs 166 workers across the globe.

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for the company is www.gamida-cell.com. The company can be reached via phone at (722) 659-5666 or via email at irpr@gamida-cell.com.